WP7 – Commercial R&D


Probably, given that most CHM were developed in a different medical theoretical system in China, the approved herbal drugs currently used in China will need further R&D before they can be safely used in the EU member states. For pharmaceutical companies in both China and EU Member States developing new herbal medicines, what industrial and legal criteria should be observed so that their products will be approvable in both Continents? WP7 will investigate if functional genomics may provide an additional and efficient component of the approval procedures of CHM for the EU …more

WP3 Stakeholders survey


The study will help defining the different factors that influence the perceptions of quality and safety of herbal medicines, notably …more

Handbook on good practice in the reporting of CHM experimental work

post image sq

How to report experimental work according to good …more

TCM Acupuncture & Herbal Practitioners survey


Electronic survey to help to inform about training, practice and common conditions treated by TCM …more

Joint WP1-WP2 Phase III Meeting

meeting photo sq

The joint phase III meeting of WP1 and WP2 was held in Braga, Portugal on 3rd – 4th December …more

Genesis Conference – Botanicals/Natural Products Stream


Genesis is reputed to be the leading biotechnology networking event in …more

GP-TCM Consortium Newsletter: January 2011 issue

title image_sq

This issue celebrates the Year of the …more

GP-TCM Consortium Newsletter: November-December 2010 issue


Merry Christmas from GP-TCM! China invests 4 billion RMB in constructing 16 National Clinical Research Bases of TCM, WHO moves to classify traditional …more

GP-TCM Consortium Newsletter: October-November 2010 issue


New EU Strategies and Policies, Revisiting UK’s Seed Cathedral in Shanghai 2010 World Expo …more

GP-TCM Consortium Newsletter: July-August 2010 issue


1st GP-TCM Annual Meeting, Joint WP1 – WP2 Phase II Kick-off Meeting, Joint WP4 – WP7 Phase II Kick-off Meeting …more